SS Innovations International reports 79% growth in SSi Mantra procedures, reaching 14,103 cumulative procedures as of Sept. 8, 2026. The company's installed base increased 42% to 238 systems from 168, and the SSi Mantra is now installed across 12 countries. SS Innovations also highlighted 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of Aug. 31. The company expects FDA review of the SSi Mantra 510(k) premarket notification by Q1 2027 and EU CE marking certification by year-end 2026.

SS Innovations

SS Innovations Reports 79% Growth in SSi Mantra Procedures, Expands Global Reach

SS Innovations reports progress in global expansion, pediatric robotic surgery, and telesurgery. The company's SSi Mantra surgical robotic system is being used in 12 countries, including India, Colombia, and Sri Lanka. The system has performed the country's first robotic-assisted cardiac surgery in Sri Lanka and over 25 other surgeries within the first three weeks. The US FDA is expected to complete its review of the SSi Mantra's 510(k) premarket notification by the end of Q1 2027.

SS Innovations Sees Robotic Surgery Expansion in Colombia, Sri Lanka

SS Innovations reported progress in global expansion, pediatric robotic surgery, and telesurgery. The company's SSi Mantra surgical robotic system has been installed in 12 countries, including Colombia and Sri Lanka. In Sri Lanka, the SSi Mantra was used for the country's first robotic-assisted cardiac surgery and over 25 other procedures. SS Innovations expects the US FDA to complete its review of the SSi Mantra by the end of Q1 2027.

SS Innovations Reports Global Expansion, Pediatric Robotic Surgery Advancements

SS Innovations International (SSII) reported Q2 revenue of $13.9 million, a 39.4% YoY increase. The company installed 30 SSi Mantra systems during the quarter, with 224 systems installed across 12 countries and over 12,000 cumulative procedures. SSII is poised for growth with potential regulatory clearance in the US and CE marking in Europe, but investors must weigh cash consumption, regulatory risk, and potential dilution against growth prospects.

SS Innovations' Q2 Revenue Up 39.4% YoY to $13.9mln Amid Global Expansion

SS Innovations International (NASDAQ: SSII) has been highlighted as a stronger growth opportunity in a Seeking Alpha analysis. The company's growth trajectory, emerging-market positioning, and lower-cost SSi Mantra surgical robotic platform make it an attractive option. SS Innovations' installed base increased 187% to 224 in Q2 FY26, and Q2 revenue rose 39% YoY. Regulatory milestones, including FDA feedback by Q1 FY27 and a European CE marketing application response by year-end 2026, are key near-term catalysts. The company's significantly lower system price compared to Intuitive Surgical's da Vinci platform supports its expansion in emerging markets and potential future entry into the US market.

SSII News